Cargando…
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
Glycoprotein VI is a platelet-specific collagen receptor critical for in vivo formation of arterial thrombosis. It is also considered as an attractive target for the development of anti-thrombotic drugs because blocking glycoprotein (GP)VI inhibits platelet aggregation without inducing detrimental e...
Autores principales: | Lebozec, Kristell, Jandrot-Perrus, Martine, Avenard, Gilles, Favre-Bulle, Olivier, Billiald, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540112/ https://www.ncbi.nlm.nih.gov/pubmed/28598281 http://dx.doi.org/10.1080/19420862.2017.1336592 |
Ejemplares similares
-
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
por: Renaud, Lionel, et al.
Publicado: (2020) -
Targeting platelet GPVI with glenzocimab: a novel mechanism for inhibition
por: Billiald, Philippe, et al.
Publicado: (2022) -
Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan
por: Jiang, Peng, et al.
Publicado: (2015) -
Collagen Can Selectively Trigger a Platelet Secretory Phenotype via Glycoprotein VI
por: Ollivier, Véronique, et al.
Publicado: (2014) -
Glycoprotein VI in securing vascular integrity in inflamed vessels
por: Boulaftali, Yacine, et al.
Publicado: (2018)